2. Search Result
Search Result
Results for "

skeletal atrophy

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112288
    C188-9
    30+ Cited Publications

    TTI-101

    		 STAT Apoptosis DNA Methyltransferase Metabolic Disease Inflammation/Immunology Cancer
    C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia .
    C188-9
  • HY-108943
    Sabinene
    2 Publications Verification

    		 Others Others
    Sabinene is an naturally occurring bicyclic monoterpene which can be used as flavorings, perfume additives, fine chemicals, and advanced biofuels. Sabinene is also an orally active compound to attenuates skeletal muscle atrophy and regulates ROS-mediated MAPK/MuRF-1 pathways .
    Sabinene
  • HY-129531
    MuRF1-IN-1

    		E1/E2/E3 Enzyme Neurological Disease
    MuRF1-IN-1 is an orally active MuRF1 inhibitor. MuRF1-IN-1 can inhibit the interaction between MuRF1 and titin as well as E3 ligase activity. MuRF1-IN-1 can alleviate skeletal muscle atrophy and dysfunction in cardiac cachexia .
    MuRF1-IN-1
  • HY-W184800
    MuRF1-IN-2

    		Bacterial E1/E2/E3 Enzyme Inflammation/Immunology
    MuRF1-IN-2 (Example 3) is a MuRF1 inhibitor. MuRF1-IN-2 can be used for research of muscle wasting conditions, of skeletal or cardial muscle atrophy .
    MuRF1-IN-2
  • HY-N3741
    Didrovaltrate

    Didrovaltratum

    		 Calcium Channel Reactive Oxygen Species (ROS) Autophagy Inflammation/Immunology Cancer
    Didrovaltrate (Didrovaltratum) is an L-type calcium channel blocker, ROS scavenger, autophagy enhancer, and lipid accumulation inhibitor. Didrovaltrate blocks L-type calcium currents in a concentration-dependent manner, shifts the current-voltage curve upward, modulates steady-state inactivation kinetics, and inhibits the nuclear translocation of glucocorticoid receptors. Didrovaltrate reduces ROS levels, downregulates the expression of muscle atrophy-related genes, enhances autophagy via lipophagy, and decreases Oleic acid-induced lipid accumulation. Didrovaltrate exhibits cytotoxic activity against cancer cells. Didrovaltrate can be used in research related to skeletal muscle atrophy, non-alcoholic fatty liver disease, breast cancer, lung cancer, gastric cancer, and prostate cancer .
    Didrovaltrate
  • HY-183504
    ActRIIB-IN-3

    		TGF-β Receptor Cancer
    ActRIIB-IN-3 is a ActRIIB inhibitor. ActRIIB-IN-3 inhibits the ActRIIB protein in the MSTN pathway and induces the reversal of skeletal muscle atrophy associated with cancer cachexia. ActRIIB-IN-3 is applicable for the research of cancer cachexia .
    ActRIIB-IN-3
  • HY-183005
    ActRIIB-IN-1

    		TGF-β Receptor Inflammation/Immunology Cancer
    ActRIIB-IN-1, 7-azaindole compound is an orally active activin type II receptor B (ActRIIB) inhibitor with an IC50 of 1.8 nM. ActRIIB-IN-1 can alleviate weight loss, muscle atrophy and decreased muscle strength caused by tumor cachexia, as well as improve appetite. ActRIIB-IN-1 can be used for the research of cancer cachexia .
    ActRIIB-IN-1
  • HY-167983
    Cx43 HC-IN-1

    		Gap Junction Protein Neurological Disease
    Cx43 HC-IN-1 (Compound D4) is a selective and orally active inhibitor of connexin hemichannels (Cx43 HC). Cx43 HC-IN-1 effectively inhibits the hemichannel activity mediated by Cx43/Cx45 in denervated skeletal muscle fibers, significantly increasing the reinnervation rate of muscle fibers by neurons. Cx43 HC-IN-1 reduces neuroinflammation and neuronal overexcitation by inhibiting hemichannels in glial cells in the brain, and alleviates epilepsy in mice. Cx43 HC-IN-1 can be used for research on epilepsy and muscle diseases .
    Cx43 HC-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: